How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,372 results for

Cushing Response

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. The Eosinophil Count Tends to Be Negatively Associated with Levels of Serum Glucose in Patients with Adrenal Cushing Syndrome Full Text available with Trip Pro

The Eosinophil Count Tends to Be Negatively Associated with Levels of Serum Glucose in Patients with Adrenal Cushing Syndrome Cushing syndrome is characterized by glucose intolerance, cardiovascular disease, and an enhanced systemic inflammatory response caused by chronic exposure to excess cortisol. Eosinopenia is frequently observed in patients with adrenal Cushing syndrome, but the relationship between the eosinophil count in peripheral blood and indicators of glucose level in patients (...) with adrenal Cushing syndrome has not been determined.A retrospective study was undertaken of the clinical and laboratory findings of 40 patients diagnosed with adrenal Cushing syndrome at Chungnam National University Hospital from January 2006 to December 2016. Clinical characteristics, complete blood cell counts with white blood cell differential, measures of their endocrine function, description of imaging studies, and pathologic findings were obtained from their medical records.Eosinophil composition

2017 Endocrinology and Metabolism

42. A rare case of an ACTH/CRH co-secreting midgut neuroendocrine tumor mimicking Cushing's disease Full Text available with Trip Pro

be compatible with Cushing's disease in ectopic CRH-secretion.High levels of CRH may induce hyperplasia of the corticotroph cells in the pituitary. This could be the cause of a preserved pituitary response to dexamethasone and CRH.Clinical features of ACTH-dependent hypercortisolism with rapid development of Cushing's syndrome, hyperpigmentation, high circulating levels of cortisol with associated hypokalemia, peripheral edema and proximal myopathy should be a warning flag of ectopic Cushing's syndrome (...) A rare case of an ACTH/CRH co-secreting midgut neuroendocrine tumor mimicking Cushing's disease Ectopic ACTH/CRH co-secreting tumors are a very rare cause of Cushing's syndrome and only a few cases have been reported in the literature. Differentiating between Cushing's disease and ectopic Cushing's syndrome may be particularly difficult if predominant ectopic CRH secretion leads to pituitary corticotroph hyperplasia that may mimic Cushing's disease during dynamic testing with both dexamethasone

2017 Endocrinology, diabetes & metabolism case reports

43. Collecting Information About Treatment Results for Patients With Cushing's Syndrome

adding more. Collecting Information About Treatment Results for Patients With Cushing's Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03364803 Recruitment Status : Recruiting First Posted : December 7, 2017 Last (...) Update Posted : October 24, 2018 See Sponsor: Memorial Sloan Kettering Cancer Center Information provided by (Responsible Party): Memorial Sloan Kettering Cancer Center Study Details Study Description Go to Brief Summary: The purpose of this study is to follow participants with Cushing's syndrome during the course of their routine care and to form a data registry to study long term participant outcomes. Condition or disease Intervention/treatment Cushing's Disease Cushing Syndrome Cushing Disease

2017 Clinical Trials

44. Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome

or more studies before adding more. Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03379363 Recruitment Status : Recruiting (...) First Posted : December 20, 2017 Last Update Posted : December 20, 2017 See Sponsor: Corcept Therapeutics Information provided by (Responsible Party): Corcept Therapeutics Study Details Study Description Go to Brief Summary: This retrospective, multi-center, chart review study will collect patient data from medical charts of pediatric patients who have been treated with Korlym for Cushing's syndrome. Condition or disease Hypercortisolism Cushing Syndrome Detailed Description: This retrospective

2017 Clinical Trials

45. A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.

studies (100). Please remove one or more studies before adding more. A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov (...) : SONICS STUDY COMPLETERS: Completed the final SONICS visit (M12) and have demonstrated maintenance of clinical response on a stable Therapeutic Dose of levoketoconazole for at least 12 weeks prior to study entry. ALL OTHERS: Confirmed newly diagnosed, persistent or recurrent endogenous Cushing's syndrome of any etiology, except secondary to malignancy (including pituitary or adrenal carcinoma). Elevated mean 24-hour UFC levels at least 1.5X upper limit of the normative range of the study's central

2017 Clinical Trials

46. Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015

). Please remove one or more studies before adding more. Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015 (CUSHING) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier (...) : NCT03297892 Recruitment Status : Not yet recruiting First Posted : September 29, 2017 Last Update Posted : October 5, 2017 See Sponsor: University Hospital, Brest Information provided by (Responsible Party): University Hospital, Brest Study Details Study Description Go to Brief Summary: Cushing's disease is a rare disease that can reduce patients' expectations or quality of life, and for which predictive factors for cardiovascular mortality and recurrence are not well defined. The primary objective

2017 Clinical Trials

47. Predictors of outcome after pituitary surgery for cushing's disease: a systematic review and meta-analysis

Predictors of outcome after pituitary surgery for cushing's disease: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

48. A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome

for the Treatment of Endogenous Cushing's Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03053271 Recruitment Status : Recruiting First Posted : February 15, 2017 Last Update Posted : February 15, 2019 See Sponsor: Millendo (...) Therapeutics US, Inc. Information provided by (Responsible Party): Millendo Therapeutics, Inc. ( Millendo Therapeutics US, Inc. ) Study Details Study Description Go to Brief Summary: This is a Phase 2 multicenter, randomized, double-blind, placebo controlled study of ATR-101 to evaluate the efficacy and safety of orally-administered ATR-101 in adults with endogenous Cushing's syndrome. Following wash-out (if needed), all eligible subjects will enter an open-label intra-subject dose-escalation period of 8

2017 Clinical Trials

49. Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment

. Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03080181 Recruitment Status : Completed First Posted : March 15, 2017 Last Update Posted : October 27, 2017 Sponsor: University of Palermo Information provided by (Responsible (...) Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2017 Clinical Trials

50. Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition

or more studies before adding more. Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03111810 Recruitment Status (...) Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2017 Clinical Trials

51. Cushing's Osteoporosis Specificities

Information provided by (Responsible Party): University Hospital, Clermont-Ferrand Study Details Study Description Go to Brief Summary: Osteoporosis induced by glucocorticoids excess constitutes the main cause of secondary osteoporosis. Most of data available are provided from cohort studies of patients treated by corticosteroids, affecting among 1% of population. In contrast, very few data on osteoporosis are available in the Cushing syndrome (CS), a rare disease affecting 1 or 2 million of inhabitants (...) Cushing's Osteoporosis Specificities Cushing's Osteoporosis Specificities - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Cushing's Osteoporosis Specificities (SOCS) The safety and scientific validity

2017 Clinical Trials

52. Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma

studies (100). Please remove one or more studies before adding more. Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma (ABACUS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03145285 Recruitment Status : Active, not recruiting First (...) Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2017 Clinical Trials

53. Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome

studies (100). Please remove one or more studies before adding more. Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov (...) such as hippocampus and frontal cortex 2 years after treatment of Cushing syndrome by using structural MRI Functional brain response [ Time Frame: 2 years ] Changes in brain functional connectivity during rest and during testing of cognitive and emotional functioning 2 years after treatment of Cushing syndrome by using functional MRI Glucose utilization [ Time Frame: 2 years ] Change in glucose utilization in the hippocampus and frontal cortex 2 years after treatment of Cushing syndrome by using Fludeoxyglucose

2017 Clinical Trials

54. ACTH after 15 minutes distinguishes between Cushing's disease and ectopic Cushing's syndrome: A proposal for a short and simple CRH test. Full Text available with Trip Pro

ACTH after 15 minutes distinguishes between Cushing's disease and ectopic Cushing's syndrome: A proposal for a short and simple CRH test. The aim of the present study was to validate criteria of corticotropin-releasing hormone (CRH) stimulation and 8 mg dexamethasone suppression (high-dose dexamethasone suppression, HDDS) to distinguish the etiology of ACTH-dependent Cushing's syndrome.We retrospectively analyzed cortisol and ACTH after the injection of 100 μg human CRH in confirmed Cushing's (...) disease (CD, n=78) and confirmed ectopic Cushing's syndrome (ECS, n=18). Cortisol and ACTH increase (in percentage above basal (%B)) at each time point, maximal increase (Δmax %B), and area under the curve (AUC %B) were analyzed using receiver operator characteristics (ROC) curve analyses. Cortisol suppression (%B) after 8 mg of dexamethasone was evaluated as a supplementary criterion.An increase in ACTH of ≥ 43%B at 15 min after CRH was the strongest predictor of CD, with a positive likelihood ratio

2015 European Journal of Endocrinology

55. Improvement and normalization of quality of life and cognitive functioning after surgical treatment for Cushing's syndrome: a systematic review and meta-analysis

Improvement and normalization of quality of life and cognitive functioning after surgical treatment for Cushing's syndrome: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2018 PROSPERO

56. The role of gene mutation in Cushing disease (CD): a systematic review

The role of gene mutation in Cushing disease (CD): a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2018 PROSPERO

57. Hippocampal volume and cognitive function in patients with Cushing's disease.ÿ A systematic review and meta-analysis of observational studies

Hippocampal volume and cognitive function in patients with Cushing's disease.ÿ A systematic review and meta-analysis of observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

58. The effects of cabergoline monotherapy in Cushing's disease: a meta-analysis

The effects of cabergoline monotherapy in Cushing's disease: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2018 PROSPERO

59. Cushing's syndrome. (Abstract)

Cushing's syndrome. Chronic exposure to excess glucorticoids results in diverse manifestations of Cushing's syndrome, including debilitating morbidities and increased mortality. Genetic and molecular mechanisms responsible for excess cortisol secretion by primary adrenal lesions and adrenocorticotropic hormone (ACTH) secretion from corticotroph or ectopic tumours have been identified. New biochemical and imaging diagnostic approaches and progress in surgical and radiotherapy techniques have

2015 Lancet

60. A dangerous Cushing response in a child: neurogenic heart damage. (Abstract)

A dangerous Cushing response in a child: neurogenic heart damage. Cushing response, which acts to preserve cerebral blood flow by inducing arterial hypertension, could induce neurogenic heart damage through hyperactivation of autonomic nervous system. Most of clinical reports describe neurogenic heart damage as a self-limiting condition clinically characterized by electrocardiographic abnormalities in the setting of an acute neurologic insult. Here we describe a case of life-threatening cardiac (...) in the setting of an acute neurologic insult. Thus, Cushing response, which is a physiological mechanism of cerebral protection, could become a double-edged sword when massive sympathetic activation makes the myocardium stunned.

2014 American Journal of Emergency Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>